Renaissance Technologies’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

Renaissance Technologies’s Portfolio STLN Stock Details STLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.77M	Buy	902,809 +180,909	+25%	+$555K	﹤0.01%	1701
2025 Q4	$2.57M	Sell	721,900 -28,600	-4%	-$106K	﹤0.01%	1709
2025 Q3	$2.62M	Buy	750,500 +293,000	+64%	+$1M	﹤0.01%	1901
2025 Q2	$938K	Buy	457,500 +209,900	+85%	+$525K	﹤0.01%	2554
2025 Q1	$282K	Buy	247,600 +65,600	+36%	+$50.8K	﹤0.01%	2944
2024 Q4	$56.2K	Buy	182,000 +12,000	+7%	+$3.11K	﹤0.01%	3369
2024 Q3	$55.6K	Sell	170,000 -169,400	-50%	-$70.2K	﹤0.01%	3334
2024 Q2	$156K	Buy	339,400 +199,300	+142%	+$170K	﹤0.01%	3095
2024 Q1	$221K	Buy	140,100 +50,800	+57%	+$96.6K	﹤0.01%	3195
2023 Q4	$182K	Buy	89,300 +17,000	+24%	+$29.5K	﹤0.01%	3161
2023 Q3	$101K	Sell	72,300 -3,342	-4%	-$3.46K	﹤0.01%	3243
2023 Q2	$42K	Sell	75,642 -56,858	-43%	-$30.1K	﹤0.01%	3646
2023 Q1	$90K	Buy	+132,500	New	+$169K	﹤0.01%	3519

Other funds holding STLN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

KWM

Kanen Wealth Management Coconut Creek, Florida $278M AUM 38.85% 1-Year Est. Return

JAIC

Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wexford Capital West Palm Beach, Florida $690M AUM 57.88% 1-Year Est. Return

CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies's STLN Position: Q1 2026 in Review

Renaissance Technologies increased its Starling Oncology Institute, Inc. Common Stock (STLN) stake by 25% in Q1 2026, buying an estimated $555K and bringing the position to 902,809 shares worth $2.77M. The position accounts for ﹤0.01% of the portfolio, ranked #1701.

Renaissance Technologies first reported a position in STLN in Q1 2023 and has held it in 13 quarters since. 115 funds tracked by Wall St. Rank hold STLN as of Q1 2026.

Renaissance Technologies held 902,809 shares of Starling Oncology Institute, Inc. Common Stock worth $2.77M as of Q1 2026.
Renaissance Technologies bought 180,909 Starling Oncology Institute, Inc. Common Stock shares in Q1 2026, an estimated $555K.
Starling Oncology Institute, Inc. Common Stock made up ﹤0.01% of Renaissance Technologies's portfolio in Q1 2026, its #1701 holding.
Renaissance Technologies first reported a position in Starling Oncology Institute, Inc. Common Stock in Q1 2023 and has held it in 13 quarters since.
115 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.